Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: J Immunol. 2023 Mar 1;210(5):595–608. doi: 10.4049/jimmunol.2200053

Figure 5. rTNFa promotes bone marrow ASC egress by downregulating CD138 expression.

Figure 5.

(A) Analysis of CD138 expression on PCs at 6 hours after PBS and rTNFa treatment in WT BM, spleen and blood. (B) Analyses of BM PCs for WT, R1KO and R2KO mice in PBS and rTNFa treated mice. Data for WT, R1KO, and R2KO mice are two pooled experiments with 3–5 mice per group. (C-E) CD138 expression in donor (D) and radiation-resistant (RR) ASCs in PBS- and rTNFa-treated DKO, R1KO, and R2KO chimeras. Data are from two pooled experiments, expect for R2KO chimera with a representative experiment in (D). (F) Gating strategy and quantification of bone marrow PCs in PBS and rTNFa-treated WT and CD138KO (B220low CD3neg CD93high CD98high) mice. Data are from two pooled experiments, with 3 mice per group. For all figures, analysis of CD138 in PBS and rTNFa-treated groups were quantified using a student T-test or Mann Whitney test for parametric and non-parametric data, respectively. *p<0.05, **p<0.01.